Expression of p53 and p21 in primary glioblastomas

Strahlentherapie und Onkologie

Volumn 181, Issue 3, 2005, Pages 164-171

  Gross, Markus W ^a,c   Kraus, Alison ^a   Nashwan, Kamal ^a   Mennel, Hans Dieter ^a   Engenhart Cabillic, Rita ^a   Schlegel, Juergen ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Glioblastoma; p21; p53; Prognostic factors

Indexed keywords

PROTEIN P21; PROTEIN P53; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER TISSUE; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MALE; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE-FREE SURVIVAL; FEMALE; GENES, P53; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TREATMENT OUTCOME;

EID: 17044407169     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1304-z     Document Type: Article

References (41)

1. Barker FG 2nd, Simmons ML, Chang SM, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:410-8.
2. Baxendine-Jones J, Campbell I, Ellison D. TP53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 1997;16:332-6.
3. Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-7.
4. Chen J, Willingham T, Shuford M, et al. Effects of ectopic overexpression of p22(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumour cells. Oncogene 1996;13:1395-403.
5. Dahm-Daphi J. p53: biology and role for cellular radiosensitivity. Strahlenther Onkol 2000;176:278-85.
6. Dulic V, Kaufmann WK, Wilson SJ, et al. TP53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-23.
7. Fan S, el Deiry WS, Bae I, et al. TP53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
8. Gerlach B, Harder AH, Hulsebos TJM, et al. Radiosensitivity and TP53, EGFR amplification and LOH 10 analysis of primary glioma cell cultures. Strahlenther Onkol 2002;178:491-6.
9. Glioma meta-analysis trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;359:1011-8.
10. Gross MW, Altscher R, Brandtner M, et al. Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin®). Strahlenther Onkol 2001;177:656-61.
11. Haas-Kogan DA, Kogan SS, Yount G, et al. TP53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys 1999;43:399-403.
12. Haas-Kogan DA, Yount G, Haas M, et al. TP53-dependent G1 arrest and TP53-independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys 1996;36:95-103.
13. Heesters M, Molenaar W, Go GK. Radiotherapy in supratentorial gliomas. A study of 821 cases. Strahlenther Onkol 2003;179:606-14.
14. Hulshof MCCM, Koot RW, Schimmel EC, et al. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution. Strahlenther Onkol 2001;177:283-90.
15. Isaacs JS, Chiao C, Merrick BA, et al. TP53-dependent p21 induction following gamma-irradiation without concomitant TP53 induction in a human peripheral neuroepithelioma cell line. Cancer Res 1997;57:2986-92.
16. Jung JM, Bruner JM, Ruan S, et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 1995;11:2021-8.
17. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
18. Khalid MH, Yagi N, Hiura T, et al. Immunohistochemical analysis of TP53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis. Brain Tumor Pathol 1998;15:89-94.
19. Kirla R, Salminen E, Huhtala S, et al. Prognostic value of the expression of tumor suppressor genes TP53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. J Neurooncol 2000;46:71-80.
20. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press, 2000.
21. Koopmann J, Maintz D, Schild S, et al. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer 1995;72:1230-3.
22. Kraus A, Gross MW, Knuechel R, et al. Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type TP53. J Neurosurg 2000;93:863-72.
23. Kraus JA, Wenghoefer M, Glesmann N, et al. TP53 gene mutations, nuclear TP53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol 2001;52:263-72.
24. Lang O, Liebermeister E, Liesegang G, et al. Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 1998;174:629-32.
25. Leenstra S, Bijlsma EK, Troost D, et al. Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. Br J Cancer 1994;70:684-9.
26. Lutterbach J, Sauerbrey W, Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol 2003;179:8-15.
27. McIlwrath A, Vasey P, Ross G, et al. Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild-type TP53 for radiosensitivity. Cancer Res 1994;54:3718-22.
28. Nieder C, Andratschke N, Wiedemann N, et al. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol 2004;180:401-7.
29. O'Connor PM, Jackman J, Bae I, et al. Characterization of the TP53 tumour suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
30. Odrazka K, Petera J, Kohlova T, et al. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma. Strahlenther Onkol 2003;179:615-9.
31. Ohgaki H, Schauble B, zur Hausen A, et al. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995;427:113-8.
32. Pykett MJ, Azzam E, Dahlberg W, et al. Differential TP53, p21, mdm2 and Rb regulation in glioma cell lines that overexpress wild-type TP53. Int J Oncol 1998;13:213-6.
33. Rasheed BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994;54:1324-30.
34. Rave-Fränk M, Glomme S, Hertig J et al. Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro. Strahlenther Onkol 2002;178:497-503.
35. Rubio MP, Deimling Avon, Yandell DW, et al. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993;53:3465-7.
36. Sambrook J, Frisch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.
37. Sauer R, Heuser A. Topoisomerase-I-Inhibitor mit potentiell strahlensensibilisierender Wirkung. Strahlenther Onkol 1997;173:125-30.
38. Schlegel J, Merdes A, Stumm G, et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994;56:72-7.
39. Wuerschmidt F, Buenemann H, Heilmann HP. Prognostic factors in high-grade malignant glioma. Strahlenther Onkol 1995;171:315-21.
40. Yao KC, Komata T, Kondo Y, et al. Molecular response of human glioblastoma multiforme cells to ionizing radiation: cell cycle arrest, modulation of the expression of cyclin-dependent kinase inhibitors, and autophagy. J Neurosurg 2003;98:378-84.
41. Yount G, Haas-Kogan D, Vidair C, et al. Cell cycle synchrony unmasks the influence of TP53 function on radiosensitivity of human glioblastoma cells. Cancer Res 1996;56:500-6.